Drug Name: Rolvedon

Active Ingredient: eflapegrastim

Indications: To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia

Approval Date: 9/9/2022

Company: Spectrum Pharmaceuticals, Inc

Learn more:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761148Orig1s000Corrected_lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *